Johns Hopkins HIV Guide
Paclitaxel
INDICATIONS
FDA
FDA
- Second-line treatment of AIDS-related Kaposi’s sarcoma
- Adjuvant therapy for node-positive breast cancer
- Second-line treatment of metastatic breast cancer
- First-line treatment of non-small cell lung cancer (in combination with cisplatin or carboplatin)
- Second-line treatment of metastatic ovarian cancer
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 4, 2016
Citation
Smith, Janessa, and Paul A Pham. "Paclitaxel." Johns Hopkins HIV Guide, 2016. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545157/all/Paclitaxel.
Smith J, Pham PA. Paclitaxel. Johns Hopkins HIV Guide. 2016. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545157/all/Paclitaxel. Accessed June 2, 2023.
Smith, J., & Pham, P. A. (2016). Paclitaxel. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545157/all/Paclitaxel
Smith J, Pham PA. Paclitaxel [Internet]. In: Johns Hopkins HIV Guide. ; 2016. [cited 2023 June 02]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545157/all/Paclitaxel.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Paclitaxel
ID - 545157
A1 - Smith,Janessa,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2016/10/04/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545157/all/Paclitaxel
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
